In numerous clinical trials, intravitreally injected anti-VEGF agents, such as bevacizumab, ranibizumab, and aflibercept, notably suppressed neovascularization and stabilized vision loss in patients with neovascular AMD [8–10] and improved retinal edema and vision in patients with diabetic macular edema [11]. Here, VEGFA is linked to diabetic macular edema.